Table 1.
Demographic and clinic-pathological characteristics.
| PC (n = 695) | V1 (n = 200) | V2 (n = 91) | V3 (n = 49) | P | |
|---|---|---|---|---|---|
| Age at diagnosis | <0.001 | ||||
| <50 | 402 (57.8) | 71 (35.5) | 37 (40.7) | 26 (53.1) | |
| ≥50 | 293 (42.2) | 129 (64.5) | 54 (59.3) | 23 (46.9) | |
| cT (%) | <0.001 | ||||
| T1–T2 | 334 (48.1) | 164 (82.0) | 57 (62.6) | 30 (61.2) | |
| T3–T4 | 361 (51.9) | 36 (18.0) | 34 (37.4) | 19 (38.8) | |
| cN (%) | <0.001 | ||||
| N0 | 58 (8.3) | 35 (17.5) | 27 (29.7) | 16 (32.7) | |
| N1–N3 | 637 (91.7) | 165 (82.5) | 64 (70.3) | 33 (67.3) | |
| HR status (%) | 0.777 | ||||
| Negative | 209 (30.1) | 59 (41.8) | 24 (26.4) | 17 (53.1) | |
| Positive | 486 (69.9) | 141 (58.2) | 67 (73.6) | 32 (46.9) | |
| HER2 status (%) | <0.001 | ||||
| Negative | 479 (68.9) | 179 (89.5) | 57 (62.6) | 27 (55.1) | |
| Positive | 216 (31.1) | 21 (10.5) | 34 (37.4) | 22 (44.9) | |
| Subtype (%) | <0.001 | ||||
| HR+/HER2− | 370 (53.2) | 134 (67.0) | 44 (48.4) | 15 (30.6) | |
| HER2+ | 216 (31.1) | 20 (10.0) | 34 (37.4) | 22 (44.9) | |
| TNBC | 109 (15.7) | 46 (23.0) | 13 (14.2) | 12 (24.5) | |
| Ki-67 index (%) | 0.002 | ||||
| Low (<20%) | 100 (14.4) | 12 (6.0) | 18 (19.8) | 7 (14.3) | |
| High (≥20%) | 595 (85.6) | 188 (94.0) | 68 (74.7) | 42 (85.7) | |
| Unknown | – | – | 5 (5.5) | – | |
| NG (%) | <0.001 | ||||
| 1/2 | 486 (69.9) | 162 (81.0) | 79 (86.8) | 42 (85.7) | |
| 3 | 209 (30.1) | 38 (19.0) | 12 (13.2) | 7 (14.3) | |
| sTILs (%) | 0.195 | ||||
| Low | 397 (57.1) | 125 (62.5) | 53 (58.2) | 20 (40.8) | |
| Moderate | 251 (36.1) | 64 (32.0) | 30 (33.0) | 25 (51.0) | |
| High | 47 (6.8) | 11 (5.5) | 8 (8.8) | 4 (8.2)) | |
| pCR (%) | <0.001 | ||||
| Yes | 169 (24.3) | 35 (17.5) | 37 (40.7) | 13 (26.5) | |
| No | 526 (75.7) | 165 (82.5) | 54 (59.3) | 36 (73.5) |
HR hormone receptor, HER2 human epidermal growth factor receptor 2, sTILs stromal tumor-infiltrating lymphocytes, NG nuclear grade, pCR pathological complete response.